Log in
NASDAQ:EXEL

Exelixis Stock Forecast, Price & News

$19.41
+0.68 (+3.63 %)
(As of 11/27/2020 12:00 AM ET)
Add
Compare
Today's Range
$18.52
Now: $19.41
$19.47
50-Day Range
$18.39
MA: $21.28
$24.80
52-Week Range
$13.67
Now: $19.41
$27.80
Volume1.74 million shs
Average Volume2.92 million shs
Market Capitalization$6.02 billion
P/E Ratio40.44
Dividend YieldN/A
Beta1.43
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, Exelixis, Inc. is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, and other kinases implicated in growth and spread of cancer. It has collaboration and license agreement with Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., Roche, Aurigene Discovery Technologies Limited, Iconic Therapeutics, Inc., Invenra, Inc., StemSynergy Therapeutics, Inc., Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Merck, Daiichi Sankyo Company, Limited, and clinical collaboration with Ipsen. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in Alameda, California.
Read More
Exelixis logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.90 out of 5 stars


Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:EXEL
CUSIP30161Q10
Phone650-837-7000
Employees617

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$967.78 million
Cash Flow$0.93 per share
Book Value$5.55 per share

Profitability

Net Income$321.01 million

Miscellaneous

Market Cap$6.02 billion
Next Earnings Date2/23/2021 (Estimated)
OptionableOptionable
$19.41
+0.68 (+3.63 %)
(As of 11/27/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EXEL News and Ratings via Email

Sign-up to receive the latest news and ratings for EXEL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Exelixis (NASDAQ:EXEL) Frequently Asked Questions

How has Exelixis' stock price been impacted by Coronavirus (COVID-19)?

Exelixis' stock was trading at $17.32 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, EXEL stock has increased by 12.1% and is now trading at $19.41.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Exelixis?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exelixis in the last year. There are currently 3 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Exelixis
.

What stocks does MarketBeat like better than Exelixis?

Wall Street analysts have given Exelixis a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Exelixis wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Exelixis' next earnings date?

Exelixis is scheduled to release its next quarterly earnings announcement on Tuesday, February 23rd 2021.
View our earnings forecast for Exelixis
.

How were Exelixis' earnings last quarter?

Exelixis, Inc. (NASDAQ:EXEL) issued its quarterly earnings results on Thursday, November, 5th. The biotechnology company reported ($0.10) EPS for the quarter, missing analysts' consensus estimates of $0.01 by $0.11. The biotechnology company had revenue of $231.10 million for the quarter, compared to analyst estimates of $215.40 million. Exelixis had a net margin of 28.21% and a return on equity of 16.40%. Exelixis's revenue was down 14.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.34 earnings per share.
View Exelixis' earnings history
.

What guidance has Exelixis issued on next quarter's earnings?

Exelixis updated its FY 2020 After-Hours earnings guidance on Thursday, November, 5th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $900-950 million, compared to the consensus revenue estimate of $922 million.

What price target have analysts set for EXEL?

11 brokerages have issued 12-month target prices for Exelixis' stock. Their forecasts range from $21.00 to $40.00. On average, they expect Exelixis' share price to reach $30.18 in the next year. This suggests a possible upside of 55.5% from the stock's current price.
View analysts' price targets for Exelixis
.

Are investors shorting Exelixis?

Exelixis saw a increase in short interest during the month of October. As of October 30th, there was short interest totaling 14,180,000 shares, an increase of 53.6% from the October 15th total of 9,230,000 shares. Based on an average daily trading volume, of 1,910,000 shares, the days-to-cover ratio is currently 7.4 days.
View Exelixis' Short Interest
.

Who are some of Exelixis' key competitors?

What other stocks do shareholders of Exelixis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Exelixis investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Intel (INTC), Alibaba Group (BABA), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Vertex Pharmaceuticals (VRTX) and AbbVie (ABBV).

Who are Exelixis' key executives?

Exelixis' management team includes the following people:
  • Dr. Stelios Papadopoulos, Co-Founder & Independent Chairman (Age 72, Pay $98k)
  • Dr. Michael M. Morrissey, CEO, Pres & Director (Age 59, Pay $2.13M)
  • Mr. Christopher J. Senner, Exec. VP & CFO (Age 52, Pay $942.26k)
  • Dr. Peter Lamb, Exec. VP of Scientific Strategy & Chief Scientific Officer (Age 59, Pay $784.71k)
  • Mr. Jeffrey J. Hessekiel, Exec. VP, Gen. Counsel & Sec. (Age 51, Pay $838.67k)
  • Dr. Gisela M. Schwab, Pres of Product Devel. & Medical Affairs and Chief Medical Officer (Age 63, Pay $1.13M)
  • Dr. Dana T. Aftab, Exec. VP of Bus. Operations
  • Ms. Susan T. Hubbard, Exec. VP of Public Affairs & Investor Relations
  • Mr. Jonathan Berndt, VP of Sales
  • Mr. Gregg Bernier, VP of Marketing

What is Exelixis' stock symbol?

Exelixis trades on the NASDAQ under the ticker symbol "EXEL."

Who are Exelixis' major shareholders?

Exelixis' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (9.91%), JPMorgan Chase & Co. (3.15%), State Street Corp (2.96%), First Trust Advisors LP (1.28%), Polar Capital LLP (1.14%) and Polar Capital LLP (1.14%). Company insiders that own Exelixis stock include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jack L Wyszomierski, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Peter Lamb, Stelios Papadopoulos and Vincent T Marchesi.
View institutional ownership trends for Exelixis
.

Which institutional investors are selling Exelixis stock?

EXEL stock was sold by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, BlackRock Inc., State Street Corp, Los Angeles Capital Management & Equity Research Inc., First Trust Advisors LP, Arrowstreet Capital Limited Partnership, Squarepoint Ops LLC, and Cubist Systematic Strategies LLC. Company insiders that have sold Exelixis company stock in the last year include Alan M Garber, Carl B Feldbaum, Christopher J Senner, George A Scangos, Gisela Schwab, Jack L Wyszomierski, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Peter Lamb, Stelios Papadopoulos, and Vincent T Marchesi.
View insider buying and selling activity for Exelixis
.

Which institutional investors are buying Exelixis stock?

EXEL stock was acquired by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, Candriam Luxembourg S.C.A., Lord Abbett & CO. LLC, Scout Investments Inc., Point72 Asset Management L.P., Blair William & Co. IL, Polar Capital LLP, and Polar Capital LLP.
View insider buying and selling activity for Exelixis
.

How do I buy shares of Exelixis?

Shares of EXEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Exelixis' stock price today?

One share of EXEL stock can currently be purchased for approximately $19.41.

How big of a company is Exelixis?

Exelixis has a market capitalization of $6.02 billion and generates $967.78 million in revenue each year. The biotechnology company earns $321.01 million in net income (profit) each year or $1.02 on an earnings per share basis. Exelixis employs 617 workers across the globe.

What is Exelixis' official website?

The official website for Exelixis is www.exelixis.com.

How can I contact Exelixis?

Exelixis' mailing address is 1851 Harbor Bay Parkway, Alameda CA, 94502. The biotechnology company can be reached via phone at 650-837-7000 or via email at [email protected]

This page was last updated on 11/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.